Over the month of August, Tilray’s seem to have had quite some trouble in Germany A number batches of the company’s CBD oil, having already been recalled early in August, are yet again failing tests for market compliance in Germany. Between the recalls of August 5th and August 20th, the company had to recall a total of six batches of an oil with 10mg/ml 1:1 THC:CBD ratio.
Tilray’s public announcements, in both cases, have been the same, mentioning how the testing of the initial batch met all parameters at the date of release and that, when checking the retained samples, the THC content of the samples resulted to be surpassing the specification offered on the products label. Between this episode and the previous one, now a total of six batches of Tilray’s oils have disappeared from the pharmacies’ shelves in Germany. Given the very peculiar nature of this medication in Germany, the issue may or may not have affected certain patients access to their medicine. Needless to say, this represents a very unpleasant situation for the company and, most likely, for some of its German customers. The affected batches had been distributed to pharmacies and pharmaceutical wholesalers between March and May. Tilray is still to make any statement in regards to how will they tackle the situation, in order to prevent such issues from reoccurring.
New MJBiz Factbook Projects a Strong Economic Impact from Marijuana Sales on Legal States and, Notably, Their Local Municipalities
Cannabis Giant Trulieve Gets Even Bigger With Harvest Health Merger
What is Delta-8 THC ?
PACT Act Revisions Dramatically Prohibit Vaping Companies direct to consumer sales